730 Comanche Court
Walnut Creek, CA 94598
Biotech and Pharmaceutical
Each year, 1.7 million Americans are diagnosed with cancer, and of those, 650,000 are treated with chemotherapy. Oncodisc is developing an implantable Digital Health device to continuously monitor chemotherapy patients and their response to treatment, while proactively alerting their physician to conditions which may require further care.
In 2017, Memorial Sloan Kettering Cancer Center published a study of 766 patients demonstrating that close patient monitoring for early intervention prolonged cancer survival by 5 months, which is greater than that of many newly approved chemotherapy agents. Preliminary regulatory evaluation suggests our initial monitoring device may be classified as 510(k) Class II.
At Oncodisc, we are staffed with the cross-functional expertise needed to improve care for future patients through monitoring, treatment algorithm development, and database analytics. Oncodisc, Inc. was founded by James Mitchell, a radiation oncologist; Andrew Thoreson, an interventional radiologist; and Teddy Johnson, a career medical device developer.